News
Libtayo Combination Achieves 19.4% Five-Year Survival in Advanced NSCLC
Pune, India | September 12, 2025 Regeneron Pharmaceuticals has shared five-year follow-up results from its Phase 3 EMPOWER-Lung 3 trial. The findings show that Libtayo
Read More